Related Experiment Videos
Preliminary data on a field study with a new hypo-allergic formula
Y Vandenplas1, M Deneyer, L Sacre
1Academic Children's Hospital, Free University of Brussels, Belgium.
Insights
A new hypoallergenic formula (HAF) prevented atopic manifestations in at-risk newborns. Infants fed HAF exclusively showed no symptoms, while others on adapted formula (AdFo) or breast milk experienced fewer issues with HAF introduction.
Area of Science:
- Pediatrics
- Allergy and Immunology
- Neonatal Nutrition
Background:
- Infants at risk for atopy often develop manifestations due to cow's milk proteins.
- Early identification and intervention are crucial for managing infant atopy.
Purpose of the Study:
- To evaluate the efficacy of a new hypoallergenic formula (HAF) in preventing atopic manifestations in high-risk newborns.
- To compare the incidence of atopy in infants fed HAF, adapted formula (AdFo), or breast milk.
Main Methods:
- A study involving five groups of 15 newborns with a positive family history of atopy.
- Infants were fed either AdFo, breast milk, or HAF for a 4-month period.
- Monitoring for the appearance and disappearance of atopic symptoms.
Main Results:
- No infants exclusively fed HAF from birth developed atopic symptoms.
- 1 out of 15 breast-fed infants and 18 out of 45 infants fed AdFo showed atopic manifestations.
- All 18 infants on AdFo with symptoms improved upon switching to HAF.
Conclusions:
- The hypoallergenic formula (HAF) shows significant promise in preventing cow's milk-related atopy in at-risk infants.
- Further research with larger populations and double-blind studies is warranted to confirm these findings.
Abstract:
The incidence of atopic manifestations due to cow's milk proteins was analysed in five groups of 15 newborns considered to be at risk for atopy because of a positive family history. All infants were studied over a 4-month period. The infants received either an adapted formula (AdFo), breast milk or a new hypo-allergic formula (HAF). Atopic manifestations appeared in 1 out of 15 breast-fed infants compared with 18 out of 45 infants fed with an AdFo. None of the infants receiving the HAF (exclusively from birth for 2-4 months) developed symptoms of atopy. Symptoms in each infant receiving an AdFo (n = 18) disappeared with the HAF. Although the results of this study are promising, data on a larger population and double-blind investigations are needed before firm conclusions can be drawn.